title: Hypoxic pulmonary vasoconstriction in isolated rat pulmonary arteries is not inhibited by antagonists of H2 S-synthesizing pathways.
abstract: An increase in the H2 S (hydrogen sulphide, hereafter sulphide) concentration in pulmonary artery smooth muscle cells (PASMCs) has been proposed to mediate hypoxic pulmonary vasoconstriction (HPV). We evaluated this hypothesis in isolated rat intrapulmonary arteries (IPAs) by examining the effects of the sulphide precursor cysteine and sulphide-synthesis blockers on HPV and also on normoxic pulmonary vasoconstriction (NPV) stimulated by prostaglandin F2α (PGF2α ) and by the drug LY83583, which causes contraction in IPAs by increasing cellular reactive oxygen species levels. Experiments with several blockers of cystathionine γ-lyase (CSE), the enzyme responsible for sulphide synthesis in the vasculature, demonstrated that propargylglycine (PAG, 1 mm) had little or no effect on the NPV caused by PGF2α or LY83583. Conversely, other CSE antagonists tested, aminooxyacetic acid (AOAA, 100 μm), β-cyanoalanine (BCA, 500 μm) and hydroxylamine (HA, 100 μm), altered the NPV to PGF2α (BCA increased, HA inhibited) and/or LY83583 (BCA increased, AOAA and HA inhibited). Preincubating IPAs in physiological saline solution (PSS) containing 1 mm cysteine increased the amplitude of the NPV to PGF2(α) by ∼50%, and had a similar effect on HPV elicited by hypoxic challenge with 0% O2 . The enhancement of both responses by cysteine was abolished by pretreatment with 1 mm PAG. Measurements carried out with an amperometric electrode demonstrated that incubation with 1 mm cysteine under anoxic conditions (to minimize sulphide oxidation) greatly potentiated the release of sulphide from pieces of rat liver and that this release was strongly antagonized by PAG, indicating that at this concentration PAG could enter cells intact and antagonize CSE. PAG at 1 mm had no effect on HPV recorded in control PSS, or in PSS supplemented with physiological concentrations of cysteine (10 μm), cystine (50 μm) and glutamate (100 μm) in order to prevent the possible depletion of intracellular cysteine during experiments. Application of a combination of 1 mm cysteine and 1 mm α-ketoglutarate to promote sulphide synthesis via the cysteine aminotransferase/mercaptopyruvate sulphurtransferase (CAT/MST) pathway caused an increase in HPV similar to that observed for cysteine. This was partially blocked by the CAT antagonist aspartate (1 mm) and also by PAG. However, HPV was not increased by 1 mm α-ketoglutarate alone, and HPV in the absence of α-ketoglutarate and cysteine was not attenuated by aspartate. Pretreatment of IPAs with dithiothreitol (DTT, 1 mm), proposed to promote the conversion of mitochondrial thiosulphate to sulphide, did not increase the release of sulphide from pieces of rat liver in either the presence or the absence of 1 mm cysteine, and virtually abolished HPV. The results provide evidence that the sulphide precursor cysteine can promote both NPV and HPV in rat IPA by generating sulphide via a PAG-sensitive pathway, presumably CSE. However, HPV evoked under control conditions was unaffected by the blockade of CSE. Moreover, HPV was not affected by the CAT antagonist aspartate and was blocked rather than enhanced by DTT. The data therefore indicate that sulphide generated by CSE or CAT/MST or from thiosulphate is unlikely to contribute to O2 sensing during HPV in these arteries.
authors: Division of Asthma, Allergy & Lung Biology, School of Medicine, King's College London, London, WC2R 2LS, UK.
authors: Jesus
authors: J
authors: Prieto-Lloret
authors: Yasin
authors: Y
authors: Shaifta
authors: Jeremy P T
authors: JP
authors: Ward
authors: Philip I
authors: PI
authors: Aaronson
mesh_terms: D000818:Animals; D003542:Cystathionine gamma-Lyase / Q000037:antagonists & inhibitors*; D003545:Cysteine / Q000494:pharmacology; D015237:Dinoprost / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006862:Hydrogen Sulfide / Q000378:metabolism*; D000860:Hypoxia / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D011651:Pulmonary Artery / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D013466:Sulfurtransferases / Q000037:antagonists & inhibitors*; D014661:Vasoconstriction
chemical_list: D004791:Enzyme Inhibitors; D015237:Dinoprost; D013466:Sulfurtransferases; D003542:Cystathionine gamma-Lyase; D003545:Cysteine; D006862:Hydrogen Sulfide
references: Br J Pharmacol. 2013 Jun;169(4):922-32
references: 23488457
references: J Comp Physiol B. 2012 Oct;182(7):881-97
references: 22430869
references: J Exp Biol. 2006 Oct;209(Pt 20):4011-23
references: 17023595
references: Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10719-24
references: 20556885
references: Biochim Biophys Acta. 2004 Jan 5;1670(1):19-27
references: 14729138
references: Am J Physiol Regul Integr Comp Physiol. 2010 Jan;298(1):R51-60
references: 19889863
references: J Physiol. 2013 Sep 15;591(Pt 18):4473-98
references: 23774281
references: Am J Physiol Regul Integr Comp Physiol. 2012 Sep 1;303(5):R487-94
references: 22739350
references: Physiol Rev. 2012 Apr;92(2):791-896
references: 22535897
references: Expert Rev Clin Pharmacol. 2011 Jan;4(1):13-32
references: 22115346
references: Life Sci. 1985 Feb 25;36(8):753-61
references: 3974409
references: Biochem Biophys Res Commun. 1994 May 30;201(1):54-62
references: 8198612
references: J Nutr. 2002 May;132(5):952-6
references: 11983820
references: Circ Res. 2010 Feb 19;106(3):526-35
references: 20019331
references: Am J Physiol Regul Integr Comp Physiol. 2005 Jan;288(1):R243-52
references: 15345473
references: Acta Med Okayama. 1982 Jun;36(3):187-97
references: 7113743
references: J Inorg Biochem. 2013 Jan;118:201-8
references: 23102503
references: Br J Pharmacol. 2014 Apr;171(8):2099-122
references: 23991830
references: Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1662-70
references: 9763541
references: Curr Opin Nephrol Hypertens. 2011 Mar;20(2):107-12
references: 21301337
references: J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):53-9
references: 20133496
references: J Appl Physiol (1985). 2012 Feb;112(3):411-8
references: 22074719
references: Free Radic Biol Med. 2009 Mar 1;46(5):633-42
references: 19103285
references: Antioxid Redox Signal. 2010 May 15;12(10):1219-34
references: 19803742
references: Free Radic Biol Med. 2011 Feb 15;50(4):495-509
references: 21130865
references: Clin Sci (Lond). 2011 Dec;121(11):459-88
references: 21843150
references: Cardiovasc Res. 2008 Feb 1;77(3):570-9
references: 18032393
references: Am J Physiol Regul Integr Comp Physiol. 2013 Sep 15;305(6):R592-603
references: 23804280
references: Acta Biochim Pol. 2004;51(3):815-24
references: 15448741
references: Biochim Biophys Acta. 2011 Nov;1814(11):1518-27
references: 21315854
references: J Clin Invest. 1960 Nov;39(11):1633-8
references: 16695834
references: Pflugers Arch. 2012 Apr;463(5):743-54
references: 22419174